Bruker (NASDAQ:BRKR) Given New $75.00 Price Target at Citigroup

Bruker (NASDAQ:BRKR) had its target price reduced by Citigroup from $80.00 to $75.00 in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Other research analysts have also issued reports about the stock. TD Cowen decreased their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday. Barclays lowered their target price on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a report on Wednesday. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Wells Fargo & Company reduced their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, The Goldman Sachs Group dropped their target price on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.36.

Bruker Stock Performance

Shares of BRKR opened at $59.34 on Wednesday. Bruker has a one year low of $54.55 and a one year high of $94.86. The company has a 50-day simple moving average of $63.97 and a two-hundred day simple moving average of $66.51. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. The firm has a market capitalization of $8.98 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 2.32 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.74 earnings per share. On average, analysts anticipate that Bruker will post 2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BRKR. Nisa Investment Advisors LLC grew its stake in shares of Bruker by 20.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 165 shares during the period. Securian Asset Management Inc. boosted its holdings in shares of Bruker by 2.3% in the second quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock worth $496,000 after buying an additional 175 shares during the last quarter. Covestor Ltd increased its holdings in Bruker by 139.1% during the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after purchasing an additional 218 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Bruker by 0.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 30,911 shares of the medical research company’s stock worth $1,972,000 after purchasing an additional 235 shares during the period. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.